News | July 21, 2022
DS-7300 Phase 2 Trial Initiated in Patients with Pretreated ExtensiveStage Small Cell Lung Cancer
DS-7300 is a specifically designed potential first-in-class B7-H3 directed antibody drug conjugate
DS-7300 is a specifically designed potential first-in-class B7-H3 directed antibody drug conjugate
Orion to receive an upfront payment of USD 290 million
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.
Bringing next-gen cannabinoid therapeutics to cancer patients
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Tislelizumab is now approved in nine indications in China
The abstract is about the cohort A, stage I of the ongoing global phase ? trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis
Opdivo-based treatments are now approved for five indications in upper gastroesophageal cancers
Lung cancer is the leading cause of cancer death in the USA, making up almost 25% of all cancer deaths
Subscribe To Our Newsletter & Stay Updated
